Results 101 to 110 of about 64,777 (328)
Human Pathology: Case Reports, 2019 Pancreatic ductal adenocarcinoma is a very aggressive neoplasm with a low survival rate, comprising the majority of pancreatic malignancies. Psammoma bodies have rarely been reported in pancreatic ductal adenocarcinoma, and their clinicopathologic ...
Hongxing Gui +3 more
doaj
Pictorial Review of Rare Pancreatic Tumors and Tumor-Like Lesions
대한영상의학회지, 2020 Various types of tumors and tumor-like lesions may affect the pancreas. Among them, pancreatic ductal adenocarcinoma is the most common and is generally referred to as “pancreatic cancer.” Recently, the detection rates of rare pancreatic tumors and ...
Seung Jae Lee +3 more
doaj +1 more source
Pancreatic Ductal Adenocarcinoma [PDF]
The American Journal of Pathology, 2019 This Guest Editorial introduces this month's special Pancreatic Cancer Theme Issue, a series of reviews intended to highlight the pathologic to molecular profiles and diagnoses of benign and neoplastic pancreatic lesions.
openaire +3 more sources
A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. [PDF]
, 2018 BACKGROUND: Variation in an individual\u27s genetic status can impact the development of pancreatic ductal adenocarcinoma; however, the majority of familial pancreatic cancers (FPC) cannot yet be attributed to a specific inherited mutation.
Brody, Jonathan +9 more
core +2 more sources
Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Molecular Oncology, EarlyView.Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson +11 more
wiley +1 more source
Acta Medica, 2003 Aim: To determine the immunoreactivity of pancreatic-polypeptide (PP) during the development of the human fetal pancreas and ductal pancreatic adenocarcinoma, given that, PP positive cells were demonstrated either into its embryonic anlage or into ...
Demetrio Tamiolakis +5 more
doaj +1 more source
Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients. [PDF]
PLoS ONE, 2013 Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. Although there are many reports using pancreatic cancer cells derived from patients who did not receive chemotherapy, characteristics of pancreatic cancer cells from ...
Kazuya Shimizu +2 more
doaj +1 more source
Oral mycobiota and pancreatic ductal adenocarcinoma
BMC Cancer, 2022 AbstractEarly detection of pancreatic ductal adenocarcinoma (PDAC) is essential for survival. Preliminary research demonstrated significant associations between structural alternation of mycobiota and PDAC. In this study, we investigated the associations between oral mycobiota and PDAC. We further explored mycobiota biomarkers for PDAC detection.
Ailin Wei +12 more
openaire +3 more sources
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma [PDF]
, 2018 Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
Daylan, Ayse Ece Cali +20 more
core +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source